CAY10572 is primarily used in biomedical research as a selective agonist of the GPR40 receptor, also known as free fatty acid receptor 1 (FFAR1). Its main application lies in the study of insulin secretion and glucose homeostasis, making it a valuable tool in diabetes research. By activating GPR40, CAY10572 enhances glucose-stimulated insulin release from pancreatic beta cells, which helps investigate pathways involved in type 2 diabetes treatment. It is also used to explore the role of GPR40 in inflammation and metabolic regulation. Due to its specificity, it supports the development and validation of new therapeutic agents targeting metabolic disorders.